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The	human	congenital	syndromes	ectrodactyly	ectodermal	dysplasia-cleft	lip/palate	syndrome,	ankylobleph-
aron	ectodermal	dysplasia	clefting,	and	split-hand/foot	malformation	are	all	characterized	by	ectodermal	
dysplasia,	limb	malformations,	and	cleft	lip/palate.	These	phenotypic	features	are	a	result	of	an	imbalance	
between	the	proliferation	and	differentiation	of	precursor	cells	during	development	of	ectoderm-derived	
structures.	Mutations	in	the	p63	and	interferon	regulatory	factor	6	(IRF6)	genes	have	been	found	in	human	
patients	with	these	syndromes,	consistent	with	phenotypes.	Here,	we	used	human	and	mouse	primary	kera-
tinocytes	and	mouse	models	to	investigate	the	role	of	p63	and	IRF6	in	proliferation	and	differentiation.	We	
report	that	the	ΔNp63	isoform	of	p63	activated	transcription	of	IRF6,	and	this,	in	turn,	induced	proteasome-
mediated	ΔNp63	degradation.	This	feedback	regulatory	loop	allowed	keratinocytes	to	exit	the	cell	cycle,	there-
by	limiting	their	ability	to	proliferate.	Importantly,	mutations	in	either	p63	or	IRF6	resulted	in	disruption	of	
this	regulatory	loop:	p63	mutations	causing	ectodermal	dysplasias	were	unable	to	activate	IRF6	transcription,	
and	mice	with	mutated	or	null	p63	showed	reduced	Irf6	expression	in	their	palate	and	ectoderm.	These	results	
identify	what	we	believe	to	be	a	novel	mechanism	that	regulates	the	proliferation-differentiation	balance	of	
keratinocytes	essential	for	palate	fusion	and	skin	differentiation	and	links	the	pathogenesis	of	2	genetically	
different	groups	of	ectodermal	dysplasia	syndromes	into	a	common	molecular	pathway.
Introduction
The p53-related transcriptional activator p63 is expressed in basal 
cells of stratified epithelia, in myoepithelial cells of the breast and 
salivary glands, and in the proliferative compartment of gastric 
mucosa (1, 2). As a result of the alternative usage of 2 promot-
ers and of complex alternative splicing, the p63 gene encodes 
6 isoforms (1). Of these, the transactivation (TA) isoforms contain 
an N-terminal TA domain, which is absent in the ΔN isoforms (1). 
In ΔNp63 isoforms, an additional TA domain has been recognized 
in the C terminus, which is responsible for ΔN-specific transcrip-
tional activities distinct from that of TA isoforms (3, 4). ΔNp63 
isoforms are expressed in cells of stratified epithelia and contrib-
ute to the regulation of the proliferative potential of epithelial 
stem cells and to epidermal morphogenesis (5–7). The critical role 
for p63 in regulating epidermal morphogenesis is illustrated by 
the phenotype of p63–/– mice, which fail to develop an epidermis, 
other stratified epithelia, and epithelial appendages (2, 8). The 
single layer of epithelial cells covering p63–/– mice at birth fails to 
provide barrier function, resulting in early postnatal lethality due 
to severe dehydration.
Mutations in the p63 gene are found in a number of dominantly inher-
ited human congenital disorders, including ectrodactyly ectodermal 
dysplasia-cleft lip/palate syndrome (EEC), ankyloblepharon ecto-
dermal dysplasia clefting (AEC), and nonsyndromic split-hand/foot 
malformation (SHFM) (9, 10). These syndromes share several phe-
notypic features, consisting of ectodermal dysplasia, limb malfor-
mations, and cleft lip/palate, that can be related to alterations of 
a tightly controlled balance between proliferation and differentia-
tion of precursor cells during the development of ectoderm-derived 
epithelia and organs (10). Since p63 is a transcription factor, the 
molecular basis of these defects most likely resides in the inability 
of mutated p63 proteins to properly activate/repress expression of 
target genes, which are beginning to be identified. Indeed, pheno-
typic defects found in p63-linked ectodermal dysplasias are com-
mon to other congenital syndromes caused by mutation in p63 
target genes, such as the DLX genes, whose mutation/misregula-
tion is associated with SHFMI (DLX5 and DLX6) (11) or with the 
trichodentoosseous syndrome (DLX3) (12), or Claudin-1, whose 
mutation leads to the NISCH syndrome (13). Interferon regulatory 
factor 6 (IRF6) is a member of a conserved family of IFN-depen-
dent transcription factors known to regulate the proliferation- 
differentiation switch in epidermal cells and shown to be required for 
palate closure during embryonic development (14–16). Mutations 
in this gene cause the van der Woude and the popliteal pterygium 
syndromes (17), conditions resembling p63-linked ectodermal dys-
plasias in many aspects (10).
Here we show that IRF6 is a p63 transcriptional target that limits 
keratinocyte proliferation by inducing ΔNp63 proteasome-medi-
ated degradation. Mutations in p63 or IRF6 disrupt this regulatory 
loop, altering the critical balance between differentiation and prolif-
eration during development, leading to clinically evident defects.
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Results
Irf6 is a direct ΔNp63 target gene. In order to identify genes specifi-
cally regulated by TAp63 or ΔNp63, we performed transcriptional 
profiling of primary mouse keratinocytes, in which TAp63 or 
ΔNp63 were selectively depleted by siRNA (13) (Supplemental 
Figure 1, A and B; supplemental material available online with 
this article; doi:10.1172/JCI40267DS1). In addition to known p63 
targets (e.g., scotin, stratifin) (Supplemental Table 1), we identified 
Irf6 as a positively regulated target in ΔNp63-depleted cells but not 
in TAp63-depleted cells (Figure 1, A and B).
Using ChIP assays, we determined that endogenous Irf6 is a direct 
p63 target in keratinocytes. We identified 2 p63-like consensus bind-
ing sites upstream of the transcription initiation site and in the first 
Irf6 intron (Figure 1C); both sites directly interact with p63 during 
calcium-induced differentiation of primary mouse keratinocytes 
(Figure 1D). Binding of p63 onto these Irf6 responsive elements 
(REs) precedes a marked increase in Irf6 mRNA and Irf6 protein levels 
(Figure 1, E and F); moreover, exogenously expressed ΔNp63 increased 
Irf6 transcript levels (Figure 1G) and induced a reporter gene driven 
by an Irf6 promoter (Supplemental Figure 1C). In contrast, an Irf6 
promoter, with the RE mutated so that it could not bind ΔNp63 in 
oligo pull-down experiments, was activated to a lesser degree by exog-
enously expressed ΔNp63 (Supplemental Figure 1, C and D).
p63 is required for Irf6 expression in vivo. To determine whether Irf6 
expression is p63-dependent in vivo, we examined the distribution 
of Irf6 mRNA using in situ hybridization on sections from wild-type 
and p63–/– mice (8). As expected, the palatal and tooth epithelia of 
p63–/– embryos displayed reduced expression of Irf6 compared with the 
heterozygous or wild-type embryos. Expression of the mesenchymal 
marker Msx1 was not significantly changed (Figure 2A), demonstrating 
the correspondence of the anatomical structures and indicating that 
the initial steps of their morphogenesis were normally induced (18). 
Reduction of Irf6 expression was confirmed by real-time quantitative 
PCR (qPCR), performed on p63–/– embryonic ectoderm (Figure 2B).
Figure 1
Irf6 is a direct p63 target. (A) Microarray analysis of Irf6 RNA expression in mouse primary keratinocytes transfected with ΔNp63- or 
TAp63-specific siRNAs. Representative heat map and raw value data are shown. (B) Irf6 mRNA expression in mouse primary keratino-
cytes transfected with ΔNp63- or TAp63-specific siRNA. Data are presented as mean ± SEM. *P = 0.001. (C) p63 REs present within the 
Irf6 gene. The p63 RE consensus sequence is shown at the bottom. Arrowheads indicate the position of primers used in ChIP analysis. 
Putative p53/p63 REs were identified by PathSearch algorithm. (D) ChIP analysis to detect p63 occupying the Irf6 promoter in differentiat-
ing mouse primary keratinocytes. PCR was performed using the indicated primers (Supplemental Methods). (E) IRF6 expression in human 
primary keratinocytes by RT-qPCR. Data are presented as mean ± SEM. (F) Immunoblot analysis of human primary keratinocyte protein 
extracts to detect IRF6, ΔNp63, K1, and PCNA proteins. (G) IRF6 expression in human primary keratinocytes transfected with the indicated 
expression vectors and induced to differentiate. ΔNp63α induces IRF6 mRNA. Data are presented as mean ± SEM. cons., consensus 
sequence; ex., exon; mIrf6, mouse Irf6; siCtr., control siRNA; siΔNp63, ΔNp63-specific siRNA; siTAp63, TAp63-specific siRNA.
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We also determined Irf6 mRNA expression levels in mouse embry-
os containing the knock-in p63 mutation R279H (found in EEC 
patients) at various developmental ages. Animals homozygous for 
this mutation were very similar to the null ones, in terms of skin, 
limb, and craniofacial defects, and displayed reduced Irf6 mRNA 
expression in the epidermis (Figure 2B) and in the tooth and pal-
ate epithelia (data not shown). Interestingly, animals heterozygous 
for this mutation show a low-penetrance, EEC-related phenotypic 
Figure 2
p63 is required for Irf6 expression in vivo. (A) The palatal phenotype in E13.5 and newborn p63–/– embryos. The age is indicated at the top col-
umns, and genotypes are reported to the left of rows. The images on the far right of each row illustrate the newborn specimens, after removal 
of the mandible (Md). The dashed black lines define the profile of the anatomical structures. In p63–/– embryos, the maxillae (Mx) and the 
secondary palate (pal II) fail to fuse with the primary palate (pal I) and the secondary palate fails to fuse on the midline (thin dashed red line, 
red asterisks). In situ hybridization for Msx1 and Irf6 on coronal sections of the tooth (E13.5, left) and palatal (E13.5, right) region of wild-type 
and p63–/– embryos. The section plane is indicated by thick dashed red lines. Expression of Msx1 is indicated with red arrows. Expression 
of Irf6 is reduced in the tooth and palate epithelia of the p63–/– specimen (black arrows and asterisks for wild-type and mutant, respectively). 
Scale bars: 1 mm (white); 50 μm (black). T, tongue. (B) RT-qPCR analysis of Irf6 mRNA in ectoderm of p63–/– mice aged E13.5 and EEC mice 
aged E16.5. The wild-type value is set as 1. Data are presented as mean ± SEM. *P = 0.01. (C) Skin sections from E16.5 wild-type (+/+) or 
p63+/EEC knock-in mice, immunostained with Irf6- or p63-specific antibodies. Irf6 immunostaining is strongly reduced in p63+/EEC mice, while 
p63 expression is increased. Images are representative of data obtained from 3 littermates for each genotype. Scale bars: 30 μm.
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spectrum, including cleft palate and ectrodactyly, that more closely 
resembles the human EEC syndrome than that of p63-null mice 
(ref. 19 and A.A. Mills et al., unpublished observations). The skin 
of p63+/EEC embryos (Figure 2C) and newborns showed patches 
of hyperproliferating epidermis; in these patches, IHC staining 
revealed a marked reduction of Irf6 nuclear expression, as compared 
with the epidermis of wild-type mice (Figure 2C, left), and a marked 
increase in p63 nuclear expression (Figure 2C, right). Consistently, 
exogenous expression of ΔNp63s carrying either the R279H or the 
Q536L mutations (the latter associated to the AEC syndrome) in 
human keratinocytes resulted in a reduced IRF6 expression com-
pared with wild-type ΔNp63 (Figure 3A). These findings were 
extended to human skin by examining IRF6 expression in biopsies 
from an AEC patient (carrying p63 I537T mutation) (13, 20). As 
shown in Figure 3B, the AEC epidermis was parakeratotic and dis-
played strong reduction in IRF6 immunoreactivity as compared 
with normal skin, also confirmed at the mRNA level (Figure 3C). 
This observation correlated with abnormally high levels of p63, 
ectopically detected in the upper epidermal layers, including the 
flattened cells of intermediate zone between the spinous layer and 
the parakeratotic stratum corneum (Figure 3B).
IRF6 induces downregulation of ΔNp63 in human keratinocytes. The 
developmental defects observed in Irf6 mutant mice are thought 
to result from the inability of Irf6 mutant cells to exit the cell 
cycle, leading to an undifferentiated hyperproliferative epidermis 
(14, 15). In addition, mice heterozygous for p63 and the Irf6 muta-
tion R84C display cleft of the secondary palate, as the medial edge 
epithelial cells fail to undergo their normal differentiation pro-
gram (21). In this regard, ΔNp63 is a key regulator of epithelial 
cell proliferative potential and is upregulated in the epidermis of 
Irf6 mutant mice (14, 15). We also noted a reciprocal relationship 
between IRF6 and p63 protein expression during calcium-induced 
differentiation of human primary keratinocytes (Figure 1F) and in 
immunofluorescence experiments performed on normal human 
epidermis (Supplemental Figure 2). Therefore, we reasoned that, 
following the initial activation of IRF6 expression by ΔNp63, IRF6 
then promotes the downregulation of ΔNp63, and that this regu-
lation might favor the exit of keratinocytes from the cell cycle. To 
test this hypothesis, we exogenously expressed IRF6 in normal 
keratinocytes and analyzed the endogenous expression of ΔNp63. 
The results indicate that IRF6-overexpressing cells display reduced 
levels of ΔNp63 (Figure 4A and Table 1).
Accordingly, ΔNp63 mRNA and protein expression is markedly 
reduced during keratinocyte differentiation (1, 22). To evaluate the 
possible role of IRF6 in differentiation-induced ΔNp63 downregula-
tion, we depleted IRF6 in human primary keratinocytes using siRNA. 
We observed that, in IRF6-depleted proliferating keratinocytes, the 
amount of ΔNp63α was similar to that in control cells, whereas differ-
entiating keratinocytes failed to induce full ΔNp63 downregulation 
and also displayed higher levels of the proliferation marker PCNA 
(Figure 4B). IRF6 depletion caused inhibition of terminal differentia-
tion, as observed by reduced levels of loricrin (LOR) mRNA in differen-
tiating IRF6-depleted cells (Supplemental Figure 3, A and B).
Downregulation of ΔNp63 during keratinocyte differentia-
tion is due, at least in part, to the expression of a specific miRNA 
(miR203) (23, 24). However, siRNA-mediated depletion of IRF6 
had no significant effect on miR203 expression, indicating that 
IRF6 is unlikely to be involved in this mechanism (Supplemental 
Figure 3C). An alternative means to downregulate ΔNp63 expres-
sion is by proteasome-mediated degradation (25, 26), and indeed, 
we found that IRF6-induced ΔNp63 protein degradation was 
mediated by the proteasome, being blocked by treatment with the 
specific inhibitor MG132 (Figure 4C), which does not affect exog-
enous ΔNp63 mRNA level (Supplemental Figure 3D). Thus, IRF6 
targets ΔNp63α and ΔNp63β isoforms for degradation but not 
ΔNp63γ or TAp63α isoforms (Supplemental Figure 4).
In addition to altered transcriptional properties, mutated ΔNp63 
might also have different sensitivity to IRF6-dependent downregu-
lation. We therefore tested the effect of IRF6 overexpression on the 
stability of the ΔNp63-R279H (EEC mutant) protein and found 
that this mutant is resistant to IRF6-mediated downregulation 
(Figure 4D). Conversely, IRF6 mutant R84C, a mutation causing 
Figure 3
p63 mutations affect IRF6 expression in vitro and in vivo. (A) IRF6 
expression in H1299 cells transfected with ΔNp63α (WT), ΔNp63α 
H279R (EEC), and ΔNp63α Q536L (AEC) expression vectors. Data are 
presented as mean ± SEM. *P = 0.01. (B) Skin sections from a newborn 
affected by AEC syndrome or from normal subjects (Ctr), immunostained 
with IRF6- and p63-specific antibodies. IRF6 expression is strongly 
downregulated in AEC epidermis. Images are representative of data 
obtained from 3 unrelated normal subjects and from 3 independent sec-
tions from the AEC patient. Scale bars: 30 μm. (C) RT-qPCR showing 
IRF6 mRNA downregulation in total RNA extracted from formalin-fixed, 
paraffin-embedded sections. Results were normalized against hARP. 
Data are presented as mean ± SEM. *P = 0.001.
research article
1574	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 5   May 2010
van der Woude syndrome, was unable to induce ΔNp63 downregu-
lation (Figure 4E). This observation correlates with increased levels 
of p63 in the perfusion medial edge epithelia and the midline epi-
thelial seam of Irf6-R84C knock-in mice palates (21). Thus, dis-
ease-related p63- and IRF6-mutant proteins are unable to estab-
lish a correct biochemical regulation, and we can postulate that in 
epithelial cells of patients affected by these mutations, the amount 
of ΔNp63 remains abnormally high, consequent to alteration of 
this regulatory pathway. Failure of p63 to be downregulated at the 
appropriate time may result in increased proliferation of epider-
mal keratinocytes or cells of the embryonic palate.
IRF6 negatively modulates the proliferative potential of epithelial cells. 
To establish a role for IRF6 in epithelial cell proliferation, we 
determined the colony-forming efficiency of epithelial cells (TE13 
cells) in which IRF6 was exogenously expressed. IRF6 overexpres-
sion resulted in a marked reduction in colony formation efficiency 
(Figure 5A). In the same assay, coexpression of normal IRF6 with 
the R279H mutated ΔNp63α, resistant to IRF6-dependent degra-
dation, restored the colony-forming efficiency to a normal level, 
while wild-type ΔNp63α did not (Figure 5A). These results suggest 
that inhibition of epithelial cell growth requires downregulation of 
ΔNp63 protein, consequent to an increased IRF6 expression, and 
that disease-causing p63 mutations compromise this regulation.
To establish a role for IRF6 in the control of the proliferative 
potential of epidermal cells, we adopted the paradigm developed 
for therapeutic epidermal transplants on human epidermis, which 
estimates the self-renewal potential of epithelial cells via the gen-
eration of holoclones, meroclones, and paraclones in vitro (27, 28). 
Figure 4
IRF6 induces downregulation of ΔNp63 in human primary keratinocytes. (A) Dual immunofluorescence on human primary keratinocytes trans-
fected with a HA-tag–IRF6 expression vector, with anti-HA and anti-p63 antibodies, to detect double-positive cells. Exogenous IRF6 decreased 
endogenous p63 expression. Arrowheads indicate transfected cells. Cell counts are reported in Table 1. Scale bar: 20 μm. (B) IRF6-depleted 
keratinocytes fail to downregulate ΔNp63 expression. Human primary keratinocytes were transfected with control (siCtr) or IRF6-specific 
(siIRF6) siRNA, followed by immunoblot detection of ΔNp63, IRF6, and PCNA. ΔNp63 was quantified by the ImageJ software, normalized, and 
expressed as fold induction (FI). (C) Immunoblot detection of HA-tag–IRF6 and ΔNp63α in U2OS cells transfected with HA-IRF6 or ΔNp63α 
expression plasmids and treated with the proteasome inhibitor MG132 (5 μM, 6 hours). MG132 treatment inhibited ΔNp63 downregulation by 
IRF6. (D) Immunoblot detection of ΔNp63α and IRF6 in H1299 cells transfected with a vector expressing either wild-type ΔNp63α or mutated 
ΔNp63α-R279H, in the presence or absence of HA-IRF6. ΔNp63α-R279H is resistant to IRF6-mediated downregulation. (E) Immunoblot detec-
tion of ΔNp63α and IRF6 in H1299 cells transfected with a ΔNp63α expression vector, in the presence of either wild-type or R84C mutant IRF6. 
The IRF6-R84C mutant failed to induce ΔNp63α downregulation. Results are representative of 3 independent experiments.
Table 1
Effect of IRF6 on p63 nuclear expression
Vector	 HA+	p63+	cells
HA-control 84% ± 15%
HA-IRF6 36% ± 10%
Results of double staining of keratinocytes transfected with control plas-
mid or HA-IRF6 expressing plasmid (Figure 4A). The percentage of HA+ 
p63+ cells present after transfection with control and HA-tag–IRF6 is 
shown. Data are presented as mean ± SEM (P = 0.001 control vs IRF6).
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We transduced primary human keratinocytes with retroviruses 
expressing IRF6 and observed that both the number and the size of 
clones generated by IRF6-expressing precursors were significantly 
lower than those obtained from control-infected cells (Figure 5B 
and Table 2). Thus, IRF6 expression reduces the proliferative 
potential of epidermal cells.
Discussion
IRF6 is a transcription factor, mutated in a subset of developmental 
syndromes, characterized by cleft lip and ectodermal dysplasia (28). 
The first important finding reported here is that in keratinocytes 
IRF6 is a direct transcriptional target of ΔNp63 but not of TAp63. 
ΔNp63 maintains basal transcription levels of IRF6 via binding to 
distal p63 REs (21) and is promptly recruited to the proximal p63 ele-
ment upon keratinocyte differentiation stimuli. This regulation most 
likely takes place in epithelial cells with high proliferative potential, 
as ΔNp63 is the predominant isoform detectable in this compart-
ment. Importantly, mutations in p63, specifically those found in 
patients with the EEC and AEC syndromes, strongly reduce or abol-
ish the ability of the ΔN protein to activate IRF6 transcription, and 
this correlates nicely with the reduced level of Irf6 protein expression 
found in the epidermis of p63R279H heterozygous animals and in the 
epidermis of the AEC patient we examined. Together, these observa-
tions suggest that misregulation of IRF6 expression contributes to 
development of the clinical phenotype of p63-related syndromes.
The second important finding is that, during epithelial cell 
differentiation, IRF6 promotes proteasome-dependent degra-
dation of ΔNp63, thus establishing a cell-autonomous negative 
regulatory loop (Figure 4C and Figure 5C). During early differ-
entiation, ΔNp63 promotes transcription of IRF6, and the IRF6 
protein in turn promotes ΔNp63 degradation. Considering that 
ΔNp63 critically endows the epidermal cells with an elevated pro-
liferation potential (7), this regulation may have the functional 
consequence of posing a limit to keratinocyte proliferation and 
allowing keratinocyte terminal differentiation and palate closure 
during embryonic development. Indeed, we show that increased 
IRF6 expression results in lower clonogenicity and reduced pro-
liferation of cultured epithelial cells.
Importantly, the mutant IRF6 proteins found in patients 
with the van der Woude syndrome are unable to bind to their 
cognate REs (29) and cannot induce p63 degradation. Thus, 
in these patients, abnormally high levels of ΔNp63 protein are 
retained in progenitor cells, with pathological consequences. 
The R279H mutant p63 is also resistant to IRF6-mediated deg-
radation, thus providing further evidence that the disruption or 
misfunctioning of the regulatory loop among these transcrip-
tion factors, either resulting in hyperactivity or in hypoactivity, 
has pathological effects.
We propose that in normal epidermal cells the negative regula-
tory loop indicated by our model is initiated by ΔNp63 binding to 
the Irf6 promoter and is subsequently needed for the exit of the 
cells from the cell-cycle and for the initiation of a tissue-specific 
differentiation program. Alterations in this molecular pathway are 
likely to affect the execution of a normal differentiation program, 
essential for the correct maturation and stratification of the epi-
dermis and for the morphogenesis of structures requiring epithe-
lial-mesenchymal interaction, such as lip/palate closure and limb 
bud patterning and growth.
In summary, our data highlight the importance of a develop-
mental feedback regulatory loop between p63 and IRF6 for the 
control of proliferation of epithelial cells and link two pheno-
typically similar, but genetically distinct, groups of ectodermal 
dysplasias into one common pathway. Future studies aimed at 
modulating this pathway for therapeutic purposes will require 
Figure 5
IRF6 negatively modulates the proliferative potential of epithelial cells. 
(A) Colony formation of TE13 epithelial carcinoma cells transfected 
with the indicated expression vectors (ΔNp63α, ΔNp63α/R279H, 
or HA-IRF6). Colonies of more than 1 mm in diameter were counted, 
and results are expressed as mean ± SEM (3 independent experi-
ments, duplicate samples). IRF6 expression induced growth arrest 
that is partially reverted by ΔNp63α-R279H coexpression. (B) Col-
ony formation of human primary keratinocytes transduced with a 
vector expressing HA-tag–IRF6. Immunoblotting shows HA-IRF6 
expression. Actin was used as loading control. The number of col-
onies that were more than 1 mm in diameter was calculated with 
ImageJ software. IRF6 expression reduced the proliferative potential 
of keratinocytes. Results are expressed as percentage of each kind 
of colony over the total (error bars = 1 SD). P = 0.01, control versus 
IRF6 (3 independent experiments, duplicate samples). The relative 
percentage of holoclones, paraclones, and meroclones is shown in 
Table 2. (C) Schematic representation of the link between ΔNp63 
and IRF6. IRF6 is transcriptionally activated by ΔNp63 during dif-
ferentiation. IRF6 protein expression induces ΔNp63 degradation, 
reducing proliferative potential of epithelial cells.
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the identification of tissue-specific IRF6 targets and the full 
comprehension of the molecular mechanisms that tightly regu-
late p63 stability/degradation.
Methods
Cell culture. Mouse and human primary keratinocytes were cultured as 
described previously. Use of mouse and human keratinocytes was approved 
by the University of Torino and the University of Rome “Tor Vergata” Insti-
tutional Review Boards, respectively (30). TE13 cells (epithelial SCC cell 
line; gift of Pierre Hainaut, International Agency for Research on Cancer, 
Lyon, France) and H1299 cells were cultured in RPMI medium containing 
10% FBS and antibiotics (100 U/ml penicillin and 10 μg/ml streptomy-
cin) at 37°C. To measure clonogenic growth, TE13 cells transfected with 
Lipofectamine (Invitrogen) were selected in G418 (600 μg/ml) (Invitrogen) 
for 15 days, before fixation in 4% PFA and staining with Crystal Violet. 
Colonies with a diameter of more than 1 mm were scored using NIH Image 
software (http://rsb.info.nih.gov/nih-image/). U2OS cells were cultured 
in DMEM containing 10% FBS and antibiotics (100 U/ml penicillin and 
10 μg/ml streptomycin) at 37°C.
Plasmids, retroviruses, and TA assays. Expression plasmids encoding for Myc-
tagged wild-type TA-ΔN-p63s and the ΔNp63α mutant R279H (EEC) have 
been reported previously (16). Human HA-tagged IRF6 expression plasmid 
was constructed by cloning the human IRF6 ORF into the pCDNA-HA vector. 
The R84C mutation was introduced in IRF6 by custom mutagenesis service 
(Biofab Research Inc.). Inserts were sequence verified.
A retroviral (pBABE-puro) expression vector with the HA-IRF6 ORF 
was derived by PCR amplification from the pCDNA plasmid. Luciferase 
reporter plasmid and retrovirus production are described in the Supple-
mental Methods.
ChIP assay. For ChIP assays, mouse primary keratinocytes were used. ChIP 
assays were performed as described previously (20). The mouse monoclonal 
antibody anti-p63 (4A4) (Santa Cruz Biotechnology Inc.) or isotypic control 
antibodies (monoclonal anti-HA [F-7] antibody; Santa Cruz Biotechnology 
Inc.) were used. PCR reactions were performed for 25–35 cycles, with an 
annealing temperature of 55°C–57°C. Primers used in ChIP assay are indi-
cated in the Supplemental Methods.
RNA interference. siRNA duplexes targeting ΔNp63, TAp63, and GFP, used 
for gene expression array (Figure 1, A and B), were obtained from MWG-Bio-
tech. Mouse primary keratinocytes, plated on collagen-coated 35-mm dishes, 
were transfected with 0.5 μg siRNA per dish using Lipofectamine 2000 
(Invitrogen). For experiments described in Figure 3B and in Supplemental 
Figure 2, we used stealth siRNAs (Invitrogen). siRNA duplexes targeting 
human IRF6 (catalog no. 1299003; Invitrogen) were used to knockdown 
IRF6 mRNA; scrambled siRNA (Invitrogen) were used as control. Human 
primary keratinocytes were plated on collagen-coated 35-mm dishes and 
transfected with 50 nM siRNAs using Lipofectamine 2000.
GeneChip and gene expression analysis. Total RNA extracted from con-
trol and ΔNp63- and TAp63-depleted human primary keratinocytes 
was used to synthesize biotinylated complementary RNA (cRNA), using 
the GeneChip One-Cycle Target Labeling and Control Reagents kit 
(Affymetrix). Fifteen μg of fragmented cRNA were used for hybridiza-
tion to GeneChip Mouse Genome 430 2.0 arrays (Affymetrix), for analy-
sis of over 39,000 transcripts. Scanning and analysis were performed as 
described previously (28). Analysis criteria are described in the Supple-
mental Methods.
Immunoblotting. The following antibodies were used: monoclonal anti-
bodies against HA (F-7) and Myc (9E10) epitopes, p63 (4A4), polyclonal 
antibodies against PCNA (PC10), and actin (C11) were purchased from 
Santa Cruz Biotechnology Inc.; anti-keratin (anti-K1) was purchased 
from Covance; mouse polyclonal anti-IRF6 from was purchased from 
Abnova Inc.; and goat polyclonal anti-IRF6 antibody (IMG3484) was pur-
chased from Imgenex. For immunoblotting, cells were lysed in 50 mM 
Tris, pH 8.0, 120 mM NaCl, and 0.5% NP-40, and protein concentration 
was determined. Forty micrograms of total cell extract were separated by 
SDS-PAGE, blotted, incubated with the antibody, and developed with the 
ECL system (Amersham Pharmacia Biotech). The MG132 inhibitor was 
from Sigma-Aldrich.
mRNA expression analysis. For RT-qPCR, total RNA was extracted using 
TRIzol Reagent (Invitrogen). One μg of total RNA was reverse transcribed 
with GeneAmp RNA PCR (Applied Biosystems). For RT-qPCR in human 
cells, the RT reaction products were used for real-time qPCR amplification, 
which was performed with the MyiQ Single-Color Real-Time Detection 
System (Bio-Rad). The human acidic ribosomal protein P0 (hARP) gene 
was used for normalization. Total RNA was extracted from formalin-fixed, 
paraffin-embedded sections using the Optimum FFPE RNA Isolation Kit 
(Ambion), according to the manufacturer’s protocol. Primer sequences are 
available in the Supplemental Methods.
Immunohistochemistry and immunofluorescence. Four-mm punch biopsy 
specimens were taken from normal skin of healthy volunteers (n = 4). 
Declaration of Helsinki protocols were followed, and patients gave writ-
ten approved consent before biopsy. Care and use of human tissues 
was approved by the University of Rome “Tor Vergata” Institutional 
Review Board. A patient affected by AEC (I537T mutation in p63) was 
subjected to skin biopsy on lesional skin, after obtaining informed con-
sent from his parents. Immunofluorescence analysis was performed on 
5 × 104 to 10 × 104 cells seeded on Chamber Slides (Nalge Nunc Interna-
tional), fixed with 4% PFA, and permeabilized with 0.2% Triton X-100. 
Immunohistochemistry and immunofluorescence were carried out by 
standard methods (Supplemental Methods).
Mouse strains and hybridization procedure. The Brdm2 mouse strain, 
also designated p63– (8), that carries a null p63 allele was genotyped by 
RT-PCR on embryonic RNA, with primers annealing to the C terminus 
of the α isoform (Trp63) mRNA. In mice carrying the p63R279H mutation 
(an EEC mutation in humans) (19), a BsaHI restriction site was abrogated 
and was used to determine the genotype, following PCR amplification 
with primers flanking codon 279. The genotype was determined by PCR 
amplification with primers flanking codon 279, followed by digestion 
with BsaHI. In situ hybridization was performed as described previously 
(31) and as described in the Supplemental Methods.
Statistics. Statistical evaluations were carried out using SigmaStat 2.03 
(SPSS). For all tests, P values of less than 0.05 were considered significant.
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